The Pan-RAS Program is focused on the discovery and development of novel indene-based small molecules. These molecules are designed to potently and selectively inhibit activated RAS signaling pathways, regardless of the specific RAS isoform or mutation present in cancer cells. Research and development activities include identifying and synthesizing novel small molecules, conducting preclinical studies to assess efficacy and safety, and exploring potential therapeutic applications across various cancer types. The program utilizes advanced medicinal chemistry, cell-based assays, and in vivo models to evaluate drug candidates. The ultimate goal is to develop effective treatments for cancers driven by RAS mutations, which are prevalent in many difficult-to-treat cancers. This segment aims to improve patient outcomes by targeting a key driver of cancer growth and progression. The company is actively seeking strategic collaborations and licensing opportunities to advance this program.

This segment focuses on identifying small molecules that selectively and potently inhibit PDE10 and suppress Wnt/APC/β-catenin signaling in preclinical models. The research and development efforts involve synthesizing and screening small molecules, conducting in vitro and in vivo studies to assess their impact on the Wnt signaling pathway, and evaluating their potential as anti-cancer agents. The program utilizes advanced molecular biology techniques, cell culture, and animal models to understand the mechanism of action and therapeutic potential of these inhibitors. The therapeutic areas of focus include cancers where the Wnt signaling pathway is dysregulated. The goal is to develop therapies that can effectively target and disrupt this pathway, leading to improved patient outcomes. The company is actively seeking strategic collaborations and licensing opportunities to advance this program.